Close Menu

NEW YORK (360Dx) – Interpace Diagnostics Group announced this week that it has entered into an agreement with Acupath Laboratories through which Acupath will sell Interpace's ThyGenX and ThyraMIR tests. ThyGenX uses next-generation sequencing to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas. ThyraMIR is a microRNA gene expression classifier.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.